Stabilized HIV-1 envelope glycoprotein trimers for vaccine use
Open Access
- 1 May 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 12 (3) , 241-249
Abstract
To provide an update on the latest developments in the field of HIV-1 antibody-based soluble envelope glycoprotein (Env) trimer design for vaccine use. The development of soluble native-like HIV-1 Env trimer immunogens has moved the field of antibody-based vaccine design forward dramatically over the past few years with refinement of various stabilizing approaches. However, despite this progress, significant challenges remain. Firstly, although trimers are relatively stable in solution, they nevertheless sample different conformational states, some of which may be less relevant to binding and induction of broadly neutralizing antibodies (bNAbs). Secondly, these trimers expose unwanted immunodominant surfaces that may distract the adaptive immune response from recognizing more immunorecessive but conserved neutralization-relevant surfaces on the trimer. The availability of atomic-resolution structural information has allowed guided design of mutations that have further stabilized trimers and allowed reduced exposure of unwanted epitopes. Moreover, chemical cross-linking approaches that do not require structural information have also contributed to trimer stabilization and selection of particular conformational forms. However, current knowledge suggests that strategies additional to trimer stabilization will be required to elicit bNAb, including targeting naïve B cell receptors with specific immunogens, and guiding B cell lineages toward recognizing conserved surfaces on Env with high affinity. This review will give a perspective on these challenges, and summarize current approaches to overcoming them with the aim of developing immunogens to elicit bNAb responses in humans by active vaccination.Keywords
This publication has 113 references indexed in Scilit:
- HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120Proceedings of the National Academy of Sciences, 2012
- B-cell–lineage immunogen design in vaccine development with HIV-1 as a case studyNature Biotechnology, 2012
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architecturesProceedings of the National Academy of Sciences, 2011
- Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodiesCurrent Opinion in Immunology, 2011
- MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1Journal of Experimental Medicine, 2011
- Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and ImmunogenicityJournal of Molecular Biology, 2010
- Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Science, 2010
- Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogensBiochemical and Biophysical Research Communications, 2009
- Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120Science, 2009